glp 1 and schizophrenia GLP-1 drugs tied to lower brain inflammation, higher depression risk Potential Role of Glucagon-like Peptide-1

Ben Lagha I, Ashack K, Khachemoune A

Finally, our studies provide important insights for efforts aimed at development of therapeutic interventions designed to inhibit dietary l-carnitine conversion into TMAO in humans

Injections were given 15 minutes prior to the onset of the dark cycle and body weight and food intake were recorded daily or every 48 h respectively, through the ~9 weeks of experimentation

Avoid tobacco products

You may have read about eloralintide , an investigational medication Eli Lilly is developing that targets the amylin pathway instead of GLP-1 and showed strong weight loss in a Phase 2 trial reported in The Lancet